Loviride
 |
|
|
Loviride
|
|
| Systematic (IUPAC) name | |
| 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C17H16Cl2N2O2 |
| Mol. mass | 351.227 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Loviride (also called Loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an NNRTI that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials Loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI's.
- Loveride
- R089439
 |
This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
